02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
23:50 , Jan 3, 2019 |  BC Extra  |  Company News

Management tracks: Barrett joins UroGen

Uro-oncology company UroGen Pharma Ltd. (NASDAQ:URGN) named Elizabeth Barrett as president and CEO. She replaces Ron Bentsur. Last month, Barrett joined the exodus of pharma leaders heading to biotech as she departed Novartis AG (NYSE:NVS;...
19:39 , Oct 10, 2018 |  BC Extra  |  Company News

Management tracks: Hamburg joins Alnylam board

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) appointed Margaret Hamburg to its board, effective Jan. 10, 2019. Hamburg is president-elect of the American Association for the Advancement of Science (AAAS), foreign secretary of the National...
20:07 , Jul 25, 2018 |  BC Extra  |  Company News

Management Tracks: Albireo, ObsEva

Pediatric liver disease company Albireo Pharma Inc. (NASDAQ:ALBO) said CMO Paresh Soni will step down. He is succeeded by Patrick Horn, who was SVP of medical and clinical development at Orphan Technologies Ltd. (Rapperswil, Switzerland)....
22:00 , Jun 18, 2018 |  BC Extra  |  Company News

Management tracks: Ionis, Albireo

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) hired Damien McDevitt as CBO. He was SVP of corporate development at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD). Hepatic disease company Albireo Pharma Inc. (NASDAQ:ALBO) hired Jason Duncan as general counsel. He was...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
19:46 , Jan 26, 2018 |  BC Week In Review  |  Financial News

GI and hepatic company Albireo raises $65M follow-on

On Jan. 25, gastrointestinal and hepatic company Albireo Pharma Inc. (NASDAQ:ALBO) raised $65 million after selling 2 million shares at $33 in a follow-on underwritten by Cowen, William Blair, Needham, Wedbush PacGrow and Roth. The...
23:03 , Jan 25, 2018 |  BC Extra  |  Financial News

Follow-on roundup: Audentes, Iovance

At least six companies have priced follow-ons since Wednesday’s market close, raising more than $600 million. Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $201.3 million after hours on Wednesday through the sale of 5.8...
19:36 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Albireo gets $55M for elobixibat approval in Japan

Albireo Pharma Inc. (NASDAQ:ALBO) nearly doubled its cash reserves after Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Goofice elobixibat to treat chronic constipation. The approval triggered about $55 million in payments to the...
16:26 , Jan 19, 2018 |  BC Extra  |  Company News

Albireo receives $55M for elobixibat approval in Japan

Albireo Pharma Inc. (NASDAQ:ALBO) nearly doubled its cash reserves after Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Goofice elobixibat on Friday to treat chronic constipation. The approval triggered about $55 million in payments...